Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

EXOSMART Exosome-Based Smart Coatings for Improved Bone Healing in Orthopaedic Implants

Coordinator
Universiteit Gent, Belgium
Runs
1 July 2026 to 30 June 2029
Status
Running
EU funding
€424k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101283322

What the project is doing

In the project's own words, from its summary on CORDIS.

Every year millions of Europeans receive orthopaedic implants such as hip and knee prostheses. While these restore mobility, up to 20% fail within 10 years mainly because of chronic inflammation. Each revision surgery costs an average of €45,000, causing suffering for patients and creating an annual burden of more than €2 billion on EU healthcare. The key reason for implant failure is uncontrolled inflammation in the immediate postoperative period (48–72hours).

During this short period immune cells called macrophages must switch from a pro-inflammatory state (M1) to a pro-healing state (M2). Current implant technologies cannot guide this transition with the required timing. EXOSMART addresses this challenge by creating smart implant coatings that release healing signals precisely when they are needed. The project harnesses exosomes, tiny vesicles naturally secreted by cells that act as biological couriers.

These vesicles are loaded with interleukin 4 (IL-4), a protein that calms inflammation and promotes the M2 state for bone repair. Three key innovations make this possible:-Engineering stem cells to produce IL-4 only under inflammatory conditions and harvesting their exosomes-Stabilising IL-4 inside exosomes to extend its bioactivity-Embedding these smart exosomes into layered titanium coatings for spatially and temporally controlled releaseThe project combines advanced bioengineering at Stanford (USA) with surface engineering expertise at UGent (Belgium).

It will generate new knowledge on immune-instructive biomaterials and deliver the first timed, biologically triggered IL-4 delivery system. For Europe, EXOSMART tackles a major medical and economic challenge. For the host institution, it brings access to complementary approaches and international collaborations. For the researcher, the fellowship provides cutting-edge expertise, fosters independence and builds a transatlantic network, laying the foundation for an independent career in biomedical innovation.

Topics

Who is involved

OrganisationCityCountryRole
Universiteit GentGentBelgiumCoordinator
Board of Trustees of the Leland Stanford Junior UniversityStanfordUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI